A recruitment shortfall can begin with an eligibility decision. A data quality problem can begin with an impractical visit schedule. A site capacity problem can begin with the accumulation of requirements that each looked reasonable when considered separately. Across SCOPE Europe 2026, discussions kept returning to these connections and to the opportunity to address problems while the decisions behind them are still open.

From feasibility and patient engagement to quality management and site operations, the emphasis was on bringing the realities of trial delivery into planning earlier. For us at SCOPE, that was one of the most consequential themes of this year's event: better execution depends on giving operational evidence more influence over what a study asks people to do.

Recruitment begins with the study being offered

Recruitment discussions repeatedly reached beyond patient identification and outreach to examine the trial itself. Eligibility criteria determine who can be considered, but they reveal only part of the population that can realistically participate. Referral pathways, local treatment practices, travel, caregiver availability, and the demands of repeated visits all shape whether an eligible patient can enroll and remain in a study.

This has implications for where recruitment expertise enters development. Once a protocol is final, teams have fewer options for addressing barriers built into its design. Earlier input from patients, coordinators, and local clinical teams creates room to reconsider those barriers before they become enrollment problems.

The same applies to inclusion. Reaching a broader population requires examining whose lives and care arrangements the protocol accommodates. Communication and community relationships matter throughout, but the design must leave people a workable route into the research. Patient engagement has its greatest opportunity to influence that route when it can still change a decision.

Site capacity is partly shaped by sponsor decisions

Across the event, site burden emerged as a constraint on research capacity. Repeated training, overlapping systems, duplicate documentation, and fragmented communication all compete for the attention of staff who also need to support participants. A sponsor may see a manageable requirement within one study; the site experiences it alongside the requirements of many others.

That difference in perspective helps explain why an improvement inside a sponsor organization may produce little benefit at the site. Moving information into a new platform can make it easier for one team to review while leaving coordinators with another place to enter the same information. Assessing efficiency across the full workflow makes that transferred work visible.

The discussions also gave site relationships a more strategic role. Sites make choices about where to commit limited resources, informed by their experience of how sponsors work. Predictable communication, responsive support, and earlier visibility into future studies therefore have implications for access to research capacity. Sustained partnerships give both sides more opportunity to plan than a succession of disconnected study requests.

Quality depends on choices about what matters

The quality discussions reinforced the case for earlier operational input. Identifying the factors critical to participant protection and reliable results during protocol development gives teams a basis for deciding what to collect, what to review closely, and where intervention will matter most.

The harder step is carrying those priorities into everyday work. If every field attracts similar scrutiny and every signal prompts another layer of review, the practical benefits of risk-based quality management remain limited. Prioritization has to affect the work assigned across data management, monitoring, and study oversight.

Simplification therefore emerged as a substantive quality decision. An unnecessary procedure creates opportunities for missed visits, incomplete data, queries, and deviations. Removing a requirement that adds little scientific value can reduce several sources of downstream work at once. The aim is to protect the evidence a trial needs while examining the effort attached to everything it asks for.

Predictability connects the study to the wider system

These themes also informed the discussion of Europe's research competitiveness. Scientific expertise and capable investigators remain central, while dependable delivery requires coordination across approvals, contracting, institutional processes, and recruitment. Improving one stage leaves other sources of delay in place unless the wider pathway receives attention.

At study level, predictability also depends on revisiting assumptions. Feasibility changes as staffing, competing trials, treatment pathways, and protocol requirements change. Keeping that knowledge connected to study decisions gives teams a better chance of responding before a missed milestone forces the conversation.

The direction suggested by SCOPE Europe 2026 is toward trial planning that stays connected to delivery. It gives patient and site experience practical influence, makes quality priorities visible in operational choices, and preserves learning as studies progress. The challenge is giving teams the authority to act on that knowledge, including when it means changing a familiar requirement.

Part 2 examines another recurring theme from SCOPE Europe 2026: what it will take for AI and connected data to produce lasting improvements in clinical research.

Continue the conversation at SCOPE Summit, March 1–4, 2027, in Orlando, Florida. Join colleagues from across clinical research to explore how better trial design, stronger site partnerships, and more connected operations can improve study delivery. Explore the program and register.